1. Home
  2. ACRV vs HDSN Comparison

ACRV vs HDSN Comparison

Compare ACRV & HDSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Acrivon Therapeutics Inc.

ACRV

Acrivon Therapeutics Inc.

HOLD

Current Price

$2.01

Market Cap

74.0M

Sector

Health Care

ML Signal

HOLD

Logo Hudson Technologies Inc.

HDSN

Hudson Technologies Inc.

HOLD

Current Price

$5.19

Market Cap

252.0M

ML Signal

HOLD

Company Overview

Basic Information
Metric
ACRV
HDSN
Founded
2018
1991
Country
United States
United States
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Industrial Specialties
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
74.0M
252.0M
IPO Year
2022
1996

Fundamental Metrics

Financial Performance
Metric
ACRV
HDSN
Price
$2.01
$5.19
Analyst Decision
Buy
Strong Buy
Analyst Count
4
3
Target Price
$11.67
$9.00
AVG Volume (30 Days)
255.5K
439.6K
Earning Date
05-08-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
15.13
N/A
EPS
N/A
0.12
Revenue
N/A
$237,118,000.00
Revenue This Year
N/A
$2.51
Revenue Next Year
$568.17
$2.38
P/E Ratio
N/A
$42.92
Revenue Growth
N/A
N/A
52 Week Low
$1.27
$4.64
52 Week High
$3.56
$10.06

Technical Indicators

Market Signals
Indicator
ACRV
HDSN
Relative Strength Index (RSI) 52.97 39.93
Support Level $1.38 $5.10
Resistance Level $2.02 $6.47
Average True Range (ATR) 0.13 0.14
MACD -0.03 0.00
Stochastic Oscillator 63.21 17.50

Price Performance

Historical Comparison
ACRV
HDSN

About ACRV Acrivon Therapeutics Inc.

Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1; ACR-2316 a selective, dual WEE1/PKMYT1 inhibitor; and ACR-6840, a development candidate targeting CDK11. It has one reportable segment focused on the research and development of precision oncology therapies.

About HDSN Hudson Technologies Inc.

Hudson Technologies Inc is a refrigerant services company providing solutions to recurring challenges within the refrigeration industry. The company delivers environmentally sustainable offerings, covering the sale of refrigerant gases, recovery, reclamation, and reuse, as well as improving equipment performance through energy efficiency services, emergency air conditioning and refrigeration system repairs, refrigerant disposal, and carbon credit trading. It operates through one reportable segment. Its products and services are used in commercial air conditioning, industrial processing, and refrigeration systems, and include refrigerant and industrial gas sales, refrigerant management services (mainly reclamation of refrigerants), and RefrigerantSide services performed at customer sites.

Share on Social Networks: